Another major project is called ‘Oral diamidines for sleeping sickness’ lead by the University of North Carolina and funded by the Gates Foundation. Recently we signed a contract with the Drugs for Neglected Diseases initiative (DNDi) for the preclinical evaluation of new compounds. The Medicines for Malaria Venture (MMV) Foundation supports the project ‘Syntheticperoxides’ and the new projects ‘Oral diamidines for malaria’. With a master contract with the MMV, we moved from individual project funding to a screening mandate for the Swiss TPH. This and the contracts with WHO/TDR and DNDi will secure the continuity of the screening unit mid- to longterm.
Two new projects were recently added to our drug discovery portfolio, drug evaluation and lead identification for animal diseases and for foodborne trematodes.